Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul;32(3):119-126.
doi: 10.1016/j.trre.2018.01.001. Epub 2018 Feb 10.

Innate networking: Thrombotic microangiopathy, the activation of coagulation and complement in the sensitized kidney transplant recipient

Miriam Manook  1 , Jean Kwun  2 , Steven Sacks  3 , Anthony Dorling  3 , Nizam Mamode  4 , Stuart Knechtle  5
Affiliations
Review

Innate networking: Thrombotic microangiopathy, the activation of coagulation and complement in the sensitized kidney transplant recipient

Miriam Manook et al. Transplant Rev (Orlando). 2018 Jul.

Abstract

Thrombotic microangiopathy (TMA) is a histological feature of antibody-mediated rejection and has the potential to cause problematic graft dysfunction, particularly for highly sensitized cross-match positive kidney transplant recipients. Prompt recognition of pertinent histopathological and systemic features of TMA in kidney transplantation is necessary. Underlying mechanisms of this process involve the activation of both complement and coagulation systems as a response to HLA antibody. As serine proteases, coagulation and complement cascades exhibit similar characteristics with respect to homeostatic function. Increasing evidence now exists for the interaction between these innate defenses in both activation and regulation, lending scope for intervention. Understanding the complexities of these interactions remains a challenge. This review provides an overview of the current understanding, particularly with respect to the activation of coagulation and complement by HLA antibody in the setting of highly sensitized kidney transplantation.

Keywords: Antibody incompatible transplantation; Coagulation; Complement; HLA-incompatible transplantation; Highly sensitized; Kidney transplantation; Thrombotic microangiopathy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest:

The authors declare no conflict of interest.

Figures

Figure 1:
Figure 1:
Complement Cascade.
Figure 2:
Figure 2:
Coagulation Cascade.
Figure 3:
Figure 3:
Complement and Coagulation Crosstalk in Thrombotic Microangiopathy in the Highly Sensitized Transplant Recipient.
See this image and copyright information in PMC

References

    1. Meri S Complement activation in diseases presenting with thrombotic microangiopathy. Eur J Intern Med. 2013;24(6):496–502. - PubMed
    1. George JN, Nester CM. Syndromes of thrombotic microangiopathy. The New England journal of medicine. 2014;371(7):654–66. - PubMed
    1. Chiurchiu C, Ruggenenti P, Remuzzi G. Thrombotic microangiopathy in renal transplantation. Ann Transplant. 2002;7(1):28–33. - PubMed
    1. Tanabe K, Tokumoto T, Ishida H, Shimmura H, Omoto K, Makiyama K, et al. Prospective analysis of thrombotic microangiopathy after renal transplantation: comparison between cyclosporine and tacrolimus immunosuppression. Transplant Proc. 2002;34(5):1819–20. - PubMed
    1. Ashman N, Chapagain A, Dobbie H, Raftery MJ, Sheaff MT, Yaqoob MM. Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2009;9(2):424–7. - PubMed

Publication types

MeSH terms